Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Gamida Cell Ltd. reported the year ended December 31, 2022 results: net income $79.4 million loss.
- Period
- the year ended December 31, 2022
- Net income
- $79.4 million loss
- Result
- reported results
Exact text from the filing
Net loss for 2022 was $79.4 million, compared to a net loss of $89.8 million in 2021.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 1.0
Gamida Cell Ltd. announced a restructuring with charges of approximately $1.1 million (approximately 17%).
- Type
- restructuring
- Charge
- approximately $1.1 million
- Headcount
- approximately 17%
Exact text from the filing
On March 27, 2023, the Company announced a workforce reduction plan (the “ Plan ”), pursuant to which it plans to downsize its current workforce by approximately 17% by the end of the second quarter of 2023. The Plan is being enacted to help extend the Company’s financial resources through the third quarter of 2023, during which time the Company intends to allocate the vast majority of its resources to executing a launch of omidubicel, if approved. Affected employees will be offered separation benefits, including severance payments and temporary healthcare coverage assistance, which severance payments, in Israel, are required under applicable law. Each affected employee’s eligibility for the separation benefits is contingent upon such employee’s execution of a separation agreement that includes a general release of claims against the Company. The Company estimates that the severance and termination-related costs will be approximately $1.1 million and expects to record these charges pri
View on SEC.gov